PremiumCompany AnnouncementsDianthus Therapeutics Reports Increased R&D Expenses Promising Outlook for Dianthus Therapeutics: Buy Rating Backed by Clinical Progress and Financial Stability Dianthus completes enrollment for Phase 2 MaGic Trial of DNTH103 PremiumRatingsOptimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress Dianthus Therapeutics: Promising Growth Potential with Innovative DNTH103 and Strong Financial Position Dianthus reports Q4 EPS (81c), consensus (76c) PremiumThe FlyDianthus price target raised to $52 from $48 at Oppenheimer Dianthus Therapeutics Reports Q3 Progress and Financials Dianthus reports Q3 EPS (74c), consensus (59c) 
